Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health shows impressive operating leverage and a scalable business model, with massive growth potential from new ...

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

In response to the news on Tuesday, the stock prices of Novo Nordisk and Hims & Hers shot up, with the latter stock price rising by nearly $10. Ro CEO Zach Reitano said, “Adding Novo Nordisk’s ...

Medical pioneers Hims & Hers Health HIMS and Novo Nordisk NVO are making headlines this week after announcing a partnership to expand obesity care in the telehealth space. The long-term ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Pharmaceutical company Novo Nordisk is teaming up with direct-to-consumer telehealth company Hims & Hers to offer discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, the companies ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...